Eris Lifesciences reports robust growth: FY26 revenue 3,129 Cr, EBITDA 1,120 Cr.

Strategic acquisitions (4,300+ Cr) and strong R&D drive expansion in Anti-Diabetes (6% share) & Insulins (16%). Sundae Gx Semaglutide launched strong.

EU-GMP observations noted; minimal impact on existing business.

FY27 revenue guided 18-20%.